Wedbush Maintains Neutral on Abivax, Lowers Price Target to $118

Benzinga Newsdesk www.benzinga.com Negative 68.4%

Neg 68.4% Neu 0% Pos 0%

Wedbush analyst David Nierengarten maintains Abivax (NASDAQ:ABVX) with a Neutral and lowers the price target from $140 to $118.